ASCO GU 2023

New updates on immunocheckpoint inhibitors and ADCs - which therapy for which patient?

Bladder preservation strategies - promising data but no change in SoC yet?!

Robust DFS benefit, but lack of OS data leaves open questions

Pembro for HR NMIBC

Re-shaping bladder cancer treatment

No change in SoC, but new genomic predictors for EV outcome

Update / German Real World Data M1 BC

PD-1 as combo in 1st line

Final OS data show no significant benefit for chemo plus ICI

No final OS difference - but subgroups may benefit from Atezolizumab

Urothelial cancer highlights from ASCO GU23

Benefit of neoadjuvant pembro for CE and CI patients

Final overall survival

Atezo monotherapy for mUC

IMvigor130: final OS

New data for pembro in HR NIMBC

Urothelial cancer - hidden gems of the poster session

3 yrs outcome of Nivo for adjuvant therapy

NMIBC highlights from ASCO GU23

Impressive DFS with adjuvant Nivo in biomarker-positive patients

Checkpoint inhibition in adjuvant therapy

Pembrolizumab in HR NIMBC

The bladder cancer highlights of ASCO GU

Exciting survival data for adjuvant NIVO

PARPi are effective in PCa - which subgroups benefits most?

BCG yanıtsız yüksek riskli KİOMK tedavisinde Pembrolizumab

Los aspectos más destacados del ASCO GU 2023 en cáncer de vejiga

The bladder cancer highlights of ASCO GU

Επισημάνσεις για τον καρκίνο του ουροθηλίου από την ASCO GU23

Refinando el tratamiento del cancere vejiga

Triplet combination - all-comer therapy or high risk high volume only? How do we identify the patients who benefit?

Benefits and risks of precision medicine with PARPi

BRCA mutations in mCRPC - the importance of biomarkers in PCa! Why we need better testing and better understanding of therapy combinations!

Normal baseline testosterone level is a strong predictor of post-ADT recovery

MMAI - a superior prognostic marker for high risk patients

ARASENS - post-hoc subgroup analysis

Formula 509: Racing to a better straegy for radiotherapy

Benefit in all groups

Monotherapy is not any longer standard of care

Surgery vs. Radiation for N1 PCa: who wins?

Controversy in ADT roundtable

ARASENS: triple independent of volume and risk

New ways to target androgen receptor signaling

Doublet or all-in: the solution for all patients?

Intensification of salvage therapy in high risk settings

mHSPC - new standard and more insights

PARP and testing

TALA ENZO with improved PFS in mCRPC

PARPi combination in mCRPC

PARPi are effective in PCa - which subgroup benefits most?

PARPi combo: all-comer treatment for mCRPC

TALA in 1st line for all patients with mCRPC

Encouraging results for Talazoparib

Rucaparib - ready for clinical practice in BRCAmut patients

Tiebreaker for previous trials

Rucaparib: treatment option for biomarker-selected patients

PARPi study with different design

Rucaparib - the new player?

Propel - final OS

PARPi combo approval for all-comers - balancing benefit of treamtent vs. side effects is crucial

PARPi & ARPi with wonderful data

miR371'in orşiektomi sonrası tedavi seçimini yönlendirmekteki yüksek doğruluğu

PARPi & ARPi με υπέροχα δεδομένα

RP sonrası kurtarma RT ile GnRH Analog ABİ APA kombinasyonu, kurtarma RT ve GnRH analog tedavisinden daha iyi PFS sağlar mı?

TALA ENZA kombinasyonu ile mKDPK olan hastalarda daha iyi progresyonsuz sağkalım

Nya vägar att blockera androgenreceptor signalering

Ny PARP hämmar studie med anna design

edavi öncesi normal testosteron seviyesi ADT sonrası testosteron geri dönüşü için güçlü bir prediktördür

Lokalize prostat kanserinde cerrahi ile SBRT karşılaştıran faz-3 randomize kontrollü çalışma

MMAI- Yüksek riskli prostat kanserinde üstün bir prognostik belirteç

Theranostics in RCC - usefull tools for ccRCC?!

Updated data of CheckMate 9ER - impact on real-world therapy

Novel updates on cabozantinib in advance RCC

First prospective data on 2nd line therapy after IO combination in mRCC

Outcomes of patients with brain metastases treated with first-line therapies

Longer FU confirms significant benefit of Nivo-Cabo, Cabo effective post IO first line

New therapy choices for renal cell cancer patients

Hypothesis-generating differences in risks groups

Reassuring update of CM9ER with longer follow up

Zircon-PET in RCC

High accuracy of miR371 to guide treatment selection after orchiectomy

Refining prediction of stage I seminoma

microbiom & CPI perspectives

Mejorando la estimacion pronostica en Seminoma Estadio I